Trial
NCT04234516
Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder
Phase IVWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
New York State Psychiatric Institute
Collaborators
—
Condition
Opioid-use Disorder
Intervention
Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film
Why stopped
PI leaving the institute
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-18